FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1985768777> ?p ?o ?g. }

• W1985768777 endingPage "777" @default.
• W1985768777 startingPage "769" @default.
• W1985768777 abstract "Malignant pleural mesothelioma (MPM) is highly intractable and readily spreads throughout the surface of the pleural cavity, and these cells have been shown to express urokinase-type plasminogen activator receptor (uPAR). We here examined the potential of our new and powerful recombinant Sendai virus (rSeV), which shows uPAR-specific cell-to-cell fusion activity (rSeV/dMFct14 (uPA2), named “BioKnife”), for tumor cell killing in two independent orthotopic xenograft models of human. Multicycle treatment using BioKnife resulted in the efficient rescue of these models, in association with tumor-specific fusion and apoptosis. Such an effect was also seen on both MSTO-211H and H226 cells in vitro; however, we confirmed that the latter expressed uPAR but not uPA. Of interest, infection with BioKnife strongly facilitated the uPA release from H226 cells, and this effect was completely abolished by use of either pyrrolidine dithiocarbamate (PDTC) or BioKnife expressing the C-terminus–deleted dominant negative inhibitor for retinoic acid-inducible gene-I (RIG-IC), indicating that BioKnife-dependent expression of uPA was mediated by the RIG-I/nuclear factor-κB (NF-κB) axis, detecting RNA viral genome replication. Therefore, these results suggest a proof of concept that the tumor cell-killing mechanism via BioKnife may have significant potential to treat patients with MPM that is characterized by frequent uPAR expression in a clinical setting. Malignant pleural mesothelioma (MPM) is highly intractable and readily spreads throughout the surface of the pleural cavity, and these cells have been shown to express urokinase-type plasminogen activator receptor (uPAR). We here examined the potential of our new and powerful recombinant Sendai virus (rSeV), which shows uPAR-specific cell-to-cell fusion activity (rSeV/dMFct14 (uPA2), named “BioKnife”), for tumor cell killing in two independent orthotopic xenograft models of human. Multicycle treatment using BioKnife resulted in the efficient rescue of these models, in association with tumor-specific fusion and apoptosis. Such an effect was also seen on both MSTO-211H and H226 cells in vitro; however, we confirmed that the latter expressed uPAR but not uPA. Of interest, infection with BioKnife strongly facilitated the uPA release from H226 cells, and this effect was completely abolished by use of either pyrrolidine dithiocarbamate (PDTC) or BioKnife expressing the C-terminus–deleted dominant negative inhibitor for retinoic acid-inducible gene-I (RIG-IC), indicating that BioKnife-dependent expression of uPA was mediated by the RIG-I/nuclear factor-κB (NF-κB) axis, detecting RNA viral genome replication. Therefore, these results suggest a proof of concept that the tumor cell-killing mechanism via BioKnife may have significant potential to treat patients with MPM that is characterized by frequent uPAR expression in a clinical setting." @default.
• W1985768777 created "2016-06-24" @default.
• W1985768777 creator A5000282495 @default.
• W1985768777 creator A5001472014 @default.
• W1985768777 creator A5004420462 @default.
• W1985768777 creator A5008259417 @default.
• W1985768777 creator A5012735404 @default.
• W1985768777 creator A5013381572 @default.
• W1985768777 creator A5016728052 @default.
• W1985768777 creator A5019855418 @default.
• W1985768777 creator A5052214679 @default.
• W1985768777 creator A5052888381 @default.
• W1985768777 creator A5055977213 @default.
• W1985768777 creator A5057126852 @default.
• W1985768777 creator A5058379711 @default.
• W1985768777 creator A5070814339 @default.
• W1985768777 creator A5080523755 @default.
• W1985768777 creator A5087166136 @default.
• W1985768777 date "2012-04-01" @default.
• W1985768777 modified "2023-09-26" @default.
• W1985768777 title "BioKnife, a uPA Activity-dependent Oncolytic Sendai Virus, Eliminates Pleural Spread of Malignant Mesothelioma via Simultaneous Stimulation of uPA Expression" @default.
• W1985768777 cites W1602370661 @default.
• W1985768777 cites W1608720736 @default.
• W1985768777 cites W1618760884 @default.
• W1985768777 cites W1969852115 @default.
• W1985768777 cites W1986109557 @default.
• W1985768777 cites W1996169907 @default.
• W1985768777 cites W2004534033 @default.
• W1985768777 cites W2046285577 @default.
• W1985768777 cites W2049631846 @default.
• W1985768777 cites W2062683162 @default.
• W1985768777 cites W2069768752 @default.
• W1985768777 cites W2075203666 @default.
• W1985768777 cites W2081787276 @default.
• W1985768777 cites W2090197687 @default.
• W1985768777 cites W2092565468 @default.
• W1985768777 cites W2114866480 @default.
• W1985768777 cites W2116576715 @default.
• W1985768777 cites W2123764828 @default.
• W1985768777 cites W2126269780 @default.
• W1985768777 cites W2134901701 @default.
• W1985768777 cites W2141137217 @default.
• W1985768777 cites W2142624689 @default.
• W1985768777 cites W2170864918 @default.
• W1985768777 cites W2174493400 @default.
• W1985768777 cites W2291438417 @default.
• W1985768777 doi "https://doi.org/10.1038/mt.2011.305" @default.
• W1985768777 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3321599" @default.
• W1985768777 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/22314292" @default.
• W1985768777 hasPublicationYear "2012" @default.
• W1985768777 type Work @default.
• W1985768777 sameAs 1985768777 @default.
• W1985768777 citedByCount "24" @default.
• W1985768777 countsByYear W19857687772012 @default.
• W1985768777 countsByYear W19857687772013 @default.
• W1985768777 countsByYear W19857687772014 @default.
• W1985768777 countsByYear W19857687772015 @default.
• W1985768777 countsByYear W19857687772016 @default.
• W1985768777 countsByYear W19857687772017 @default.
• W1985768777 countsByYear W19857687772019 @default.
• W1985768777 countsByYear W19857687772020 @default.
• W1985768777 countsByYear W19857687772021 @default.
• W1985768777 countsByYear W19857687772022 @default.
• W1985768777 crossrefType "journal-article" @default.
• W1985768777 hasAuthorship W1985768777A5000282495 @default.
• W1985768777 hasAuthorship W1985768777A5001472014 @default.
• W1985768777 hasAuthorship W1985768777A5004420462 @default.
• W1985768777 hasAuthorship W1985768777A5008259417 @default.
• W1985768777 hasAuthorship W1985768777A5012735404 @default.
• W1985768777 hasAuthorship W1985768777A5013381572 @default.
• W1985768777 hasAuthorship W1985768777A5016728052 @default.
• W1985768777 hasAuthorship W1985768777A5019855418 @default.
• W1985768777 hasAuthorship W1985768777A5052214679 @default.
• W1985768777 hasAuthorship W1985768777A5052888381 @default.
• W1985768777 hasAuthorship W1985768777A5055977213 @default.
• W1985768777 hasAuthorship W1985768777A5057126852 @default.
• W1985768777 hasAuthorship W1985768777A5058379711 @default.
• W1985768777 hasAuthorship W1985768777A5070814339 @default.
• W1985768777 hasAuthorship W1985768777A5080523755 @default.
• W1985768777 hasAuthorship W1985768777A5087166136 @default.
• W1985768777 hasBestOaLocation W19857687771 @default.
• W1985768777 hasConcept C134018914 @default.
• W1985768777 hasConcept C142724271 @default.
• W1985768777 hasConcept C1491633281 @default.
• W1985768777 hasConcept C153911025 @default.
• W1985768777 hasConcept C185592680 @default.
• W1985768777 hasConcept C2776892390 @default.
• W1985768777 hasConcept C2777407522 @default.
• W1985768777 hasConcept C2779679481 @default.
• W1985768777 hasConcept C3020616263 @default.
• W1985768777 hasConcept C502942594 @default.
• W1985768777 hasConcept C54355233 @default.
• W1985768777 hasConcept C56219504 @default.
• W1985768777 hasConcept C71924100 @default.
• W1985768777 hasConcept C82210918 @default.
• W1985768777 hasConcept C86803240 @default.
• W1985768777 hasConceptScore W1985768777C134018914 @default.
• W1985768777 hasConceptScore W1985768777C142724271 @default.

• next